KENSEY NASH ANNOUNCES COMPLETION OF CAROTID PILOT TRIAL USING THE TRIACTIV PROGUARD SYSTEM

Kensey Nash Corporation today announced that it has completed enrollment of a pilot trial for its TriActiv ProGuard Embolic Protection System in carotid stenting procedures. Data from the study will support a CE Mark application for use of the device during carotid stenting procedures. It also will support an IDE submission to the U.S. Food and Drug Administration (FDA) to begin a larger pivotal trial in the U.S. for the same indication. The U.S. pivotal trial is expected to commence during the summer of 2006. PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/04-26-2006/0004347777&EDATE=)